# Pasatru (garetosmab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/garetosmab

> The FDA approved Pasatru (garetosmab), sponsored by REGENERON PHARMACEUTICALS, INC. (REGN), on Aug 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Pasatru (garetosmab) |
| Codes | REGN2477 |
| Sponsor | REGENERON PHARMACEUTICALS, INC. (REGN) https://sec-api.dev/companies/regn/catalysts |
| Indications | [with fibrodysplasia ossificans progressiva](https://sec-api.dev/indications/with-fibrodysplasia-ossificans-progressiva), Fibrodysplasia Ossificans Progressiva |
| Modality | antibody |
| FDA designations | priority review |

## Timeline

### July 17, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Fibrodysplasia Ossificans Progressiva.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05394116 (A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-17 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT05394116

### Feb 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month. Indication: with fibrodysplasia ossificans progressiva.
- First seen 2026-04-29, last confirmed 2026-04-29.
- Press release filed with the SEC (EX-99) (accession 0000872589-26-000014): "•In February 2026, the FDA accepted for priority review the Biologics License Application (BLA) for garetosmab (an Activin A antibody) for the treatment of adults with fibrodysplasia ossificans progressiva (FOP), which has a target action date in August 2026." https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/exhibit991q12026.htm

### Aug 2026: PDUFA date

- Status: scheduled. Date confidence: month. Indication: with fibrodysplasia ossificans progressiva.
- First seen 2026-01-30, last confirmed 2026-04-29.
- Press release filed with the SEC (EX-99) (accession 0000872589-26-000014): "•In February 2026, the FDA accepted for priority review the Biologics License Application (BLA) for garetosmab (an Activin A antibody) for the treatment of adults with fibrodysplasia ossificans progressiva (FOP), which has a target action date in August 2026." https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/exhibit991q12026.htm
- Press release filed with the SEC (EX-99) (accession 0000872589-26-000004): "FDA decision on BLA and EC decision on MAA for garetosmab (Activin A antibody) in FOP (second half 2026)" https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/exhibit991q42025.htm

### Aug 2026: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2026-10-30, last confirmed 2026-10-30.
- Press release filed with the SEC (EX-99) (accession 0000872589-26-000032): "•In August 2026, the FDA approved Pasatru to reduce formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP." https://www.sec.gov/Archives/edgar/data/872589/000087258926000032/exhibit991q32026.htm

### Jul to Oct 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Fibrodysplasia Ossificans Progressiva; FOP.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07559513 (A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-07-08 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07559513

### July 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Fibrodysplasia Ossificans Progressiva; FOP.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07559513 (A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-07-08 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07559513

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/garetosmab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Pasatru (garetosmab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/garetosmab

```bibtex
@misc{secapidev_pdufa_garetosmab_20261116,
  title        = {Pasatru (garetosmab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/garetosmab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_garetosmab_20261116","title":"Pasatru (garetosmab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/garetosmab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
